|
311 Outcomes
of consultation on patient choice to help develop NHS services Pharmacists
are being asked to contribute to a Government consultation in England
on patient choice ...more
311 Pharmacy
schools to take part in networks looking at patients safety Two
schools of pharmacy are to take part in multidisciplinary networks designed
to bring together researchers looking at different aspects of patient
safety issues ...more
312 More
evidence against low INR targets Patients who receive inadequate
anticoagulation therapy have a substantially increased risk of death
and severe disability from atrial fibrillation-related stroke, according
to researchers from Harvard Medical School, Boston ...more
312 CoaguChek
PT strips recalled The Medicines and Healthcare products Regulatory
Agency has issued a medical device alert regarding the recall of a batch
of CoaguChek PT test strips by Roche Diagnostics ...more
312 Valsartan
reduces atrial fibrillation risk for heart failure patients Valsartan
reduces the risk of atrial fibrillation (AF) by 35 per cent in heart
failure patients, according to new data from the Val-HeFT trial ...more
312 Updated
glitazone licence includes oral monotherapy indication Rosiglitazone
(Avandia) and pioglitazone (Actos) can now be used as monotherapy in
type 2 diabetes ...more
312 Glitazones
linked to heart failure Thiazolidinediones, also known as
glitazones, may cause pulmonary oedema or exacerbate heart failure, according
to the authors of a new study ...more
313 ETP
to be developed as part of the new NHS integrated care records service Electronic
transmission of prescriptions (ETP) will be included in England in the
integrated care records service (ICRS), the Department of Health said
this week ...more
313 Control
of entry changes warning The Government's proposed changes
to the control of entry regulations might reduce rather than increase
competition and choice for patients, according to the United Co-operative
Group ...more
313 Pharmacy
card sent to MSPs Three pharmacy organisations in Scotland
are working together to inform Members of the Scottish Parliament (MSPs)
about pharmacy ...more
313 Drug
misuse leaflet Leaflets providing information about treatment
for drug addiction are being sent to community pharmacies this week ...more
314 Avoid
changes to statin therapy if no good reason Statin therapy should not be stopped or changed without good reason, a review published in Bandolier concludes
...more
314 New
European guidelines extend measures to prevent heart disease New
guidelines from the European Society of Cardiology extend measures for
the prevention of heart disease and recommend more aggressive targets
for blood pressure and cholesterol lowering in high-risk patients ...more
314 Warning
issued about venlafaxine use in children in United States A
warning that venlafaxine (Efexor) should not be used in children under
18 years has been issued in the United States ...more |
315 Pharmacy
conditions survey heralds launch of new defence association A
survey of the conditions under which employee and locum community pharmacists
work is being undertaken as part of the launch of the Pharmacists' Defence
Association (PDA), a new legal service ...more
315 Pharmacists
paid for successful interventions by Eastbourne PCT Community
pharmacists in Eastbourne will be paid £5 for each successful intervention
they make as part of an independent medicines management scheme run by
Eastbourne Downs Primary Care Trust ...more
315 PSNC makes
awards Four awards of £2,500 each have been made by
the Pharmaceutical Services Negotiating Committee under its community
pharmacy development scheme to local pharmaceutical committees to promote
new services or developments of existing services ...more
315 Malaria awareness
extended A malaria fact card developed by the International
Pharmaceutical Federation (FIP) and the Commonwealth Pharmaceutical Association
is to be published in African local dialects, including Swahili and six
local dialects in Ghana ...more
RESEARCH & DEVELOPMENT
316 Ximelagatran
reduces post-MI events The direct thrombin inhibitor ximelagatran
(Exanta) reduces the risk of death, recurrent heart attack or severe
chest pain by nearly one-quarter after six months' treatment on top of
standard therapy, including aspirin. This finding comes from the first
study of this new oral anticoagulant in patients who have had a myocardial
infarction (MI) ...more
316 New hopes
for medicinal use of cranberries and tea Compounds extracted
from cranberries and tea have potential uses in stroke and skin cancer,
respectively, according to reports from the American Chemical Society
meeting in New York this week ...more
316 Addiction
vaccine in development A new vaccine for the treatment of
addiction is being developed partly in Britain ...more
316 New target
for cancer cells American and English researchers are using
nitroreductase to target cytotoxic agents to cancer cells ...more
316 Diarrhoea
vaccine under trial Berkshire company Microscience is testing
a one-dose vaccine for travellers' diarrhoea in phase I clinical trials
...more
317 Alternative
to peak flow meter coming soon An alternative device to the
peak flow meter has been developed at Brunel University and could be
on the market within 12 to 18 months ...more
317 Gut hormone
shows promise as new treatment for obesity “An attractive
therapeutic option for obesity,” is how scientists describe administration
of a gut hormone which has been found to reduce appetite in both lean
and overweight volunteers ...more |
